Clinical trials: Acute Phase
COVID-19
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
The purpose of this study is to learn about the side effects (safety) of the study medicine PF-07321332 (nirmatrelvir)/ritonavir for the treatment of mild to moderate COVID-19 infection in adults with severe renal impairment.
- Trial name
- NCT05487040
- Testing
- PF-07321332 (nirmatrelvir)/ritonavir
- Where
- 52 sites in United States
- Volunteers
- 15 people
- Sponsor
- Pfizer
Leukemia, Myeloid, Acute
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
Phase III, multicenter, randomized study with two arms (1:1 ratio) enrolling patients with AML relapsed/refractory after 2, 3, or 4 prior induction regimens: Experimental arm: DFP-10917 14-day continuous intravenous (IV) infusion…
- Trial name
- NCT03926624
- Testing
- DFP-10917, Cytarabine, Azacitidine
- Where
- 39 sites in United States
- Volunteers
- 167 people
- Sponsor
- Delta-Fly Pharma, Inc.
Solid Tumors, Leukemia, Lymphocytic, Acute, Pediatric
Clofarabine in Adult Patients With Advanced Solid Tumors
Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed acute lymphoblastic leukemia (ALL) who have had at least 2 prior treatment…
- Conditions
- Solid Tumors, Leukemia, Lymphocytic, Acute, Pediatric, Leukemia, Lymphocytic, Acute, Adult, Leukemia, Myelocytic, Acute, Pediatric
- Trial name
- NCT00125840
- Testing
- clofarabine (IV formulation)
- Where
- 2 sites in United States
- Sponsor
- Genzyme, a Sanofi Company
Stroke
Efficacy and Safety of Metamizole Versus Placebo as Antithermic Therapy in the Acute Phase of Ischemic Stroke
Clinical efficacy and safety of Metamizole 2 g i.v. versus placebo, as antithermic therapy in the acute phase of ischemic stroke.
- Trial name
- ATIS (NCT02184260)
- Testing
- Metamizole
- Volunteers
- 58 people
- Sponsor
- Boehringer Ingelheim
Acute Promyelocytic Leukemia
Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL
This is a Phase II, open-label, non-randomized study to evaluate the safety, efficacy, and pharmacokinetics of tamibarotene in adult patients with relapsed or refractory acute promyelocytic leukemia (APL) following treatment with…
- Trial name
- STAR-1 (NCT00520208)
- Testing
- Tamibarotene
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- CytRx
Coronavirus, Covid19
A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19
This study aims to evaluate the safety (in all participants) and reactogenicity (in a subset of participants) of CVnCoV administered as a 2-dose schedule to adult participants 18 years of age or older.
- Conditions
- Coronavirus, Covid19, SARS-CoV-2, Severe Acute Respiratory Syndrome
- Trial name
- NCT04674189
- Testing
- CVnCoV Vaccine
- Where
- Germany
- Volunteers
- 2,357 people, healthy volunteers welcome
- Sponsor
- CureVac
Myelogenous Leukemia, Acute, Leukemia, Lymphocytic, Acute
Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247)
This study of SCH 900776 (MK-8776) will evaluate its safety and tolerability when given in combination with cytarabine to participants with acute leukemias.
- Conditions
- Myelogenous Leukemia, Acute, Leukemia, Lymphocytic, Acute, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Myelogenous Leukemia, Chronic, Aggressive Phase
- Trial name
- NCT00907517
- Testing
- MK-8776, Cytarabine
- Volunteers
- 24 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.
Acute myeloid leukemia is a malignant disorder characterized by the rapid, uncontrolled proliferation of malignant clonal hematopoietic stem cells that accumulate as immature, undifferentiated cells (blasts) in the bone marrow…
- Trial name
- NCT04275518
- Testing
- APG-115, Azacitidine, Cytarabine
- Where
- 14 sites in China
- Volunteers
- 102 people
- Sponsor
- Ascentage Pharma Group Inc.
Myelogenous Leukemia, Acute, Myelodysplastic Syndromes
MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease
In this study, MGCD0103, a new anticancer drug under investigation, is given three times per week to elderly patients with previously untreated acute myelogenous leukemia/high risk myelodysplastic syndrome or adults with…
- Trial name
- NCT00374296
- Testing
- MGCD0103
- Where
- 13 sites in United States, Canada
- Volunteers
- 35 people
- Sponsor
- Mirati Therapeutics Inc.
Leukemia
A Study in Participants With Acute Leukemia
This study is a multicenter, non-randomized, open-label, Phase 2 study of intravenous LY2090314 in participants with acute leukemia.
- Trial name
- NCT01214603
- Testing
- LY2090314
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Eli Lilly and Company
Adenoviral Conjunctivitis
Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Viral Conjunctivitis
A Phase 2, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of IVIEW-1201 (1.0% Povidone-Iodine) Gel Forming Ophthalmic Solution Compared to Placebo in the Treatment of Adenoviral…
- Trial name
- NCT03749317
- Testing
- IVIEW-1201
- Where
- India
- Volunteers
- 135 people
- Sponsor
- IVIEW Therapeutics Inc.
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia in Remission
Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation
A phase 1b, open label, multi-center trial of AB-110 in adults with hematologic malignancies, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplasia (MDS) undergoing cord blood…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia in Remission, Myelodysplastic Syndromes, Other Acute Leukemias
- Trial name
- NCT03483324
- Testing
- Unmanipulated Umbilical Cord Blood (UCB), AB-110
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Angiocrine Bioscience
Graft Vs Host Disease, Graft-versus-host-disease
RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation
This Phase II open label study will evaluate the safety and efficacy of repeat doses of RGI-2001 in combination with standard of care treatment for the prevention of acute graft-vs-host-disease (aGvHD) in subjects following…
- Conditions
- Graft Vs Host Disease, Graft-versus-host-disease, Acute-graft-versus-host Disease, Prevention of aGVHD
- Trial name
- NCT04014790
- Testing
- RGI-2001, Standard of Care
- Where
- 7 sites in United States
- Volunteers
- 49 people
- Sponsor
- Regimmune Corporation
Safety, Antitumor Activity
FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms
This is a Phase 2, open-label, multicenter study to safety \& tolerability, antitumor activity, and pharmacokinetics of FCN-338 in Combination with szacitidine (AZA) or chemotherapy(erythromycin, cytarabine(Ara-C)) in Patients…
- Conditions
- Safety, Antitumor Activity, PK Profile
- Trial name
- NCT06858618
- Testing
- FCN-338 + Azacitidine, FCN-338 + erythromycin+ Ara-C
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Acute Migraine With or Without Aura
Study to Assess the Safety and Efficacy of ONZETRA® Xsail® for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents
This study will be conducted to evaluate the safety and efficacy of sumatriptan nasal powder (AVP-825) compared to placebo in the acute treatment of migraine in adolescent participants, 12 through 17 years of age.
- Trial name
- NCT03338920
- Testing
- sumatriptan nasal powder
- Where
- 40 sites in United States
- Volunteers
- 159 people
- Sponsor
- Currax Pharmaceuticals
B-cell Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia
Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients
This was a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of an experimental therapy called CTL019 T-cells in pediatric patients with B-cell acute lymphoblastic leukemia, who were…
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia, Refractory B-cell Acute Lymphoblastic Leukemia
- Trial name
- ENSIGN (NCT02228096)
- Testing
- CTL019 T-cells
- Where
- 13 sites in United States
- Volunteers
- 75 people
- Sponsor
- Novartis Pharmaceuticals
Acute Ischemic Stroke
A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects
This Phase 1 study is planned to establish the clinical safety and pharmacokinetics profile of multiple dose of LT3001 drug product and to investigate drug interactions of LT3001 with potential concomitant medications in healthy…
- Trial name
- NCT04809818
- Testing
- LT3001 drug product, Aspirin, Clopidogrel
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Lumosa Therapeutics Co., Ltd.
Acute Pain, Postoperative Pain Control
An Efficacy and Safety Study of LTG-001 Following Abdominoplasty
The goal of this clinical trial is to learn if LTG-001 works to treat post-operative / acute pain after an abdominoplasty procedure. It will also learn more information on the safety of LTG-001.
- Trial name
- NCT07102459
- Testing
- Experimental: LTG-001 High Dose, Experimental: LTG-001 Low Dose, Active Comparator: HB/APAP
- Where
- 5 sites in United States
- Volunteers
- 343 people
- Sponsor
- Latigo Biotherapeutics
Acute Ischemic Stroke
Compound Edaravone Injection for Acute Ischemic Stroke
1. To investigate the efficacy and safety of multi-doses Compound Edaravone Injection versus Edaravone Injection for acute ischemic stroke patients; 2.
- Trial name
- NCT01929096
- Testing
- Compound Edaravone Injection, Edaravone Injection
- Where
- 28 sites in China
- Volunteers
- 400 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Nausea, Vomiting
Safety and Efficacy of Palonosetron in Preventing Chemotherapy-induced Nausea and Vomiting
The purpose of this study is to determine whether palonosetron is tolerate and effective in preventing chemotherapy-induced nausea and vomiting in oriental population.
- Conditions
- Nausea, Vomiting, Chemotherapy
- Trial name
- NCT00503386
- Testing
- Palonosetron, Granisetron
- Where
- 6 sites in China
- Volunteers
- 144 people
- Sponsor
- Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.